Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Acorda Therapeutics"
Count: 55
Selected: 0
NCT IDTitle
NCT01839279A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial
NCT00041717Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury
NCT02242487Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
NCT03887884Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
NCT02352363Randomized Safety Study of CVT-301 Compared to an Observational Control Group
NCT02240030Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
NCT02422940Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
NCT01750684AC105 in Patients With Acute Traumatic Spinal Cord Injury
NCT02474407Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)
NCT00127530Study of Oral Fampridine-SR in Multiple Sclerosis
NCT02398461An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
NCT01777555Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
NCT02316847An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.
NCT02271217A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
NCT02905227A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
NCT01683838Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury
NCT01617135Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
NCT01417078A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode
NCT02807675A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
NCT02812394A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets
NCT02633839A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults
NCT01944683A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure
NCT02663999A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers
NCT02633007A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma
NCT02609945Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
NCT00483652Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
NCT01605825A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
NCT01803867An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
NCT01258387Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure
NCT01468350Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
NCT01535664An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
NCT01328379Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
NCT01405950Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy
NCT01316055Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment
NCT00654927Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
NCT00649792Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
NCT00648908Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
NCT00053417Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
NCT03051607Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
NCT03200080A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users
NCT03212313Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant
NCT01337986Ampyra for Optic Neuritis in Multiple Sclerosis
NCT01356940A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis
NCT02166346Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
NCT01491022A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
NCT01975324A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT01811706Dalfampridine and Gait in Spinocerebellar Ataxias
NCT01215084A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers
NCT01235221Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.
NCT01444300Dalfampridine for Imbalance in Multiple Sclerosis